Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
NLSP
NLS Pharmaceutics AG
Kadimastem's allogeneic cell-therapy platform (IsletRx, AstroRx) and NLSP's merger create a clear Cell Therapy business line.
|
$894150 |
$0.79
-72.35%
|
|
INIS
Radnostix, Inc.
Core product: INIS manufactures radiopharmaceutical drugs (I-131) used for diagnostic imaging and therapy.
|
$670373 |
$0.09
|
|
PRPH
ProPhase Labs, Inc.
BE-Smart uses a biomarker-based diagnostic panel, aligning with companion diagnostics.
|
$623118 |
$0.36
+127.99%
|
|
CDT
CDT Equity Inc.
AZD1656/AZD5658 are small-molecule therapeutics licensed for development.
|
$398063 |
$1.01
-2.88%
|
|
SLRX
Salarius Pharmaceuticals, Inc.
Salarius operates as a clinical-stage biotech focused on oncology therapies (e.g., LSD1 inhibitor seclidemstat) and develops cancer treatments.
|
$397571 |
$0.74
-5.36%
|
|
ZVSA
ZyVersa Therapeutics, Inc.
IC 100 is a humanized monoclonal IgG4 antibody targeting ASC, classifiable as Monoclonal Antibody Therapeutics.
|
$359547 |
$0.14
|
|
RGBP
Regen BioPharma, Inc.
Pipeline includes HemaXellarate, dCellVax, tCellVax, and DuroCAR, representing cell therapy modalities.
|
$224038 |
$0.01
|
|
SXTC
China SXT Pharmaceuticals, Inc.
SXTC manufactures TCMP products and operates GMP-compliant production lines, consistent with a contract manufacturing organization (CMO) model.
|
$183510 |
$2.02
+1.00%
|
|
CMND
Clearmind Medicine Inc.
CMND-100 is an oral small-molecule therapeutic candidate, categorizing the company under Oral Small Molecule Therapeutics.
|
$160038 |
$1.18
-0.84%
|
|
PLRZ
Polyrizon Ltd.
Polyrizon's core offering is a proprietary intranasal hydrogel-based drug delivery platform (Capture & Contain and Trap & Target) used to deliver allergy blockers and CNS-targeted APIs.
|
$37634 |
$13.35
-0.82%
|
|
CERO
CERo Therapeutics Holdings, Inc.
CERO Therapeutics develops oncology-focused immunotherapies, including CER-T engineered T-cell therapies for cancer.
|
$14826 |
$0.10
+141.50%
|
|
EMMA
Emmaus Life Sciences, Inc.
Endari is an oral small-molecule therapeutic (L-glutamine) marketed by Emmaus Life Sciences for sickle cell disease.
|
$14040 |
$0.01
|
|
SMFL
Smart for Life, Inc.
SMFL owns manufacturing facilities (BSNM and DSO) and provides contract manufacturing for branded and contract-made nutraceutical products.
|
$558 |
$0.00
|
|
NCNA
NuCana plc
NuCana is a clinical-stage oncology biotech focusing on cancer therapeutics (NUC-3373 and NUC-7738).
|
N/A |
$2.17
+2.11%
|
Showing page 25 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
